Crossmark

Development of LC-MS/MS methods affording identification and measurement of active metabolites in rat and dog plasma after oral dosing of a penta-ethyl ester prodrug of diethylenetriamine pentaacetic acid

Crossref DOI link: https://doi.org/10.1007/s00044-024-03264-6

Published Online: 2024-07-30

Published Print: 2024-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kagel, John R. https://orcid.org/0009-0003-1769-8935
Jay, Michael https://orcid.org/0000-0003-4114-9007
Zamboni, William C. https://orcid.org/0000-0002-8319-4482
Funding

Funding for this research was provided by:

National Institute of Allergy and Infectious Diseases (HHSN266200500045C)
License Information

Text and Data Mining valid from 2024-07-30

Version of Record valid from 2024-07-30
More Information

Article History

Received: 4 May 2024

Accepted: 18 June 2024

First Online: 30 July 2024

Compliance with ethical standards

:

: JRK and WCZ declare that they have no conflict of interest. MJ is a co-founder of Capture Pharmaceuticals, which owns intellectual property related to C2E5. However, no financial support from Capture Pharmaceuticals was provided in these studies.

Document is current

Any future updates will be listed below